ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
Sector:
Finance
Industry:
Financial Conglomerates
Employees:
7
Frequently Asked Questions
What is Market Cap of ZyVersa Therapeutics Inc - Ordinary Shares - Class A?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. ZyVersa Therapeutics Inc - Ordinary Shares - Class A market cap is $225.66M.
What is the 52-week high for ZyVersa Therapeutics Inc - Ordinary Shares - Class A?
52 week high is the highest price of a stock in the past 52 weeks, or one year. ZyVersa Therapeutics Inc - Ordinary Shares - Class A 52 week high is $25.00 as of September 26, 2025.
What is the 52-week low for ZyVersa Therapeutics Inc - Ordinary Shares - Class A?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. ZyVersa Therapeutics Inc - Ordinary Shares - Class A 52 week low is $9.25 as of September 26, 2025.
What is ZyVersa Therapeutics Inc - Ordinary Shares - Class A stock price today?
ZyVersa Therapeutics Inc - Ordinary Shares - Class A stock price today is $22.50.
What was ZyVersa Therapeutics Inc - Ordinary Shares - Class A stock price yesterday?
ZyVersa Therapeutics Inc - Ordinary Shares - Class A stock price yesterday was $9.69.
What is the PE ratio of ZyVersa Therapeutics Inc - Ordinary Shares - Class A?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. ZyVersa Therapeutics Inc - Ordinary Shares - Class A’s P/E ratio is -111.00.
What is the Price-to-Book ratio of ZyVersa Therapeutics Inc - Ordinary Shares - Class A?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. ZyVersa Therapeutics Inc - Ordinary Shares - Class A P/B ratio is 3.0332.
What is ZyVersa Therapeutics Inc - Ordinary Shares - Class A's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. ZyVersa Therapeutics Inc - Ordinary Shares - Class A's EBITDA is -0.04.
What is the 50-day moving average of ZyVersa Therapeutics Inc - Ordinary Shares - Class A?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. ZyVersa Therapeutics Inc - Ordinary Shares - Class A 50-day moving average is $10.33.
How many employess does ZyVersa Therapeutics Inc - Ordinary Shares - Class A has?
ZyVersa Therapeutics Inc - Ordinary Shares - Class A has 7 employees.
